Athebio
athebio.com
Actively hiring
Biologics & Biosimilars
Drug Discovery
As featured in
View 1 job
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
News
Athebio AG appoints Thomas Huber, PhD, as CEO
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Der Beitrag Athebio AG appoints Thomas Huber, PhD, as CEO erschien zuerst auf Athebio.
Read more
Report
Athebio AG appoints Dr. Jens Hennecke to its Board of Directors
Der Beitrag Athebio AG appoints Dr. Jens Hennecke to its Board of Directors erschien zuerst auf Athebio.
Read more
Report
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Der Beitrag POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands erschien zuerst auf Athebio.
Read more
Report
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope deliveryINDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the
Read more
Report
Shareholders of Athebio AG elect Dr. Hans-Peter Gerber as new member of the Board of Directors
Der Beitrag Shareholders of Athebio AG elect Dr. Hans-Peter Gerber as new member of the Board of Directors erschien zuerst auf Athebio.
Read more
Report
Athebio Enters Development and License Agreement with Acuitas Therapeutics
Der Beitrag Athebio Enters Development and License Agreement with Acuitas Therapeutics erschien zuerst auf Athebio.
Read more
Report
Athebio AG appoints Dr. Hans-Peter Gerber as Scientific Advisor
Der Beitrag Athebio AG appoints Dr. Hans-Peter Gerber as Scientific Advisor erschien zuerst auf Athebio.
Read more
Report
Athebio Enters Collaboration Agreement with 3T Biosciences
Der Beitrag Athebio Enters Collaboration Agreement with 3T Biosciences erschien zuerst auf Athebio.
Read more
Report
Athebio Enters Research Agreement with REGENXBIO
Der Beitrag Athebio Enters Research Agreement with REGENXBIO erschien zuerst auf Athebio.
Read more
Report
Athebio AG appoints Dr. Victor Levitsky as Scientific Adviso
Der Beitrag Athebio AG appoints Dr. Victor Levitsky as Scientific Adviso erschien zuerst auf Athebio.
Read more
Report
Tech stack
Technologies named in job postings at Athebio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
7
Postings analysed
1
Stack modernity
78/100AI adopter
Languages
Python
Developer tools
Benchling
LIMS
AI & ML
Claude
Practices & domains
AI Agents
Agentic Workflows
Next-Generation Sequencing
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
38/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
AI/ML
100% ▼
Activity Timeline
Added Next-Generation Sequencing to stack
Oct 2026
Added LIMS to stack
Oct 2026
Added Benchling to stack
Oct 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Zurich
Zurich
Switzerland
HQ
1 open roles 1 posted in 90 days 100% engineering 10-50 est. staff
hires for AI/ML
Jobs
≈ $137k – $341k per year (Estimated) · In office · Full-Time · 5+ years exp · PhD · Zurich
Python
Claude
AI Agents
Agentic Workflows
Life Sciences
Next-Generation Sequencing
LIMS
Benchling
Apply